ARTICLE | Clinical News

Vical tumbles after ischemia miss

September 23, 2010 12:50 AM UTC

Vical Inc. (NASDAQ:VICL) fell $1.24 (32%) to $2.62 on Wednesday after partner sanofi-aventis Group (Euronext:SAN; NYSE:SNY) said intramuscular riferminogen pecaplasmid ( NV1FGF) missed the primary endpoint in the Phase III TAMARIS trial to treat critical limb ischemia (CLI). The non-viral DNA plasmid encoding fibroblast growth factor-1 (FGF-1) was not superior to placebo in preventing major amputation or death from any cause over 12 months. The double-blind, international trial enrolled 525 patients with CLI and skin lesions who were not eligible for revascularization. sanofi said it is evaluating all options for NV1FGF development. ...